No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 3,247 | 3,805 | 3,560 | 2,893 | 2,876 | 2,568 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 584 | 924 | 288 | 94 | 108 | 412 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1958 and based in Jinhua, China, Zhejiang Jianfeng Group Co., Ltd. is a diverse enterprise primarily engaged in the Chinese cement industry, providing both ordinary Portland and Portland slag cement. Beyond construction materials, Jianfeng Group manufactures a range of pharmaceutical goods. These encompass aspartic acid amlodipine tablets for managing hypertension; heart pills designed to alleviate symptoms of high blood pressure, dizziness, headaches, neck pain, coronary heart disease, angina, nervous headaches, and early sudden deafness; paroxetine hydrochloride tablets targeting anxiety associated with depression; vinegar acid chloride Finn zyban products to treat symptoms linked to osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; spray vials for individuals suffering from severe herpes zoster; and sodium hyaluronate eye drops for dry eye conditions. Its diverse portfolio further includes a variety of cable products. Among these are common insulated electric wires for general and household use (BV line), HYA series communication cables featuring copper cores and solid polyolefin insulation, network lines, RVV series main power cables, SYWV-75 series physical foaming cables, and other telecommunication wiring. The group also supplies health and wellness items, ranging from Boiling Jade Kim tea bags, Bomb sugar, Sangge tea, lyophilized Tianma pieces, and broken fungus spore powder, to various capsules like grape seed extract soft, Tianfu, vitamin E nutritional, Bone Thai, and Goodnight capsules. Completing its array of services, the company also manages warehousing and logistics. All its offerings reach customers via an established network of marketing and sales channels.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Zhejiang Jianfeng Group Co., Ltd. (600668.SS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1958 and based in Jinhua, China, Zhejiang Jianfeng Group Co., Ltd. is a diverse enterprise primarily engaged in the Chinese cement industry, providing both ordinary Portland and Portland slag cement. Beyond construction materials, Jianfeng Group manufactures a range of pharmaceutical goods. These encompass aspartic acid amlodipine tablets for managing hypertension; heart pills designed to alleviate symptoms of high blood pressure, dizziness, headaches, neck pain, coronary heart disease, angina, nervous headaches, and early sudden deafness; paroxetine hydrochloride tablets targeting anxiety associated with depression; vinegar acid chloride Finn zyban products to treat symptoms linked to osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; spray vials for individuals suffering from severe herpes zoster; and sodium hyaluronate eye drops for dry eye conditions. Its diverse portfolio further includes a variety of cable products. Among these are common insulated electric wires for general and household use (BV line), HYA series communication cables featuring copper cores and solid polyolefin insulation, network lines, RVV series main power cables, SYWV-75 series physical foaming cables, and other telecommunication wiring. The group also supplies health and wellness items, ranging from Boiling Jade Kim tea bags, Bomb sugar, Sangge tea, lyophilized Tianma pieces, and broken fungus spore powder, to various capsules like grape seed extract soft, Tianfu, vitamin E nutritional, Bone Thai, and Goodnight capsules. Completing its array of services, the company also manages warehousing and logistics. All its offerings reach customers via an established network of marketing and sales channels.
